Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf your weight loss on Mounjaro has slowed or stalled, the most useful thing to know first is this: the dose you are on does most of the deciding. Tirzepatide's licensed titration schedule starts low and steps upward for clinical reasons, and the bulk of the evidence for significant weight reduction comes from the higher maintenance doses — not the early weeks. That said, dose alone is not the whole picture. Diet quality, protein intake, activity, sleep, and a few common habits that quietly blunt the medicine's effect all contribute. Mounjaro is a prescription-only medicine; a GPhC-registered prescriber decides whether and when your dose should change, not a calculator or a forum post.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Most people searching this question have hit a frustrating flat spell and assume the answer is simply a bigger dose. Sometimes it is. But dose increases on Mounjaro follow a minimum four-week schedule for tolerability reasons, and no reputable prescriber will accelerate that timeline simply because progress has slowed for two weeks. Plateaus during titration are physiologically normal. Your body adapts to a reduced calorie intake over time, metabolic rate adjusts, and what looked like a slow month may precede a faster one.
There is also a subtler point worth sitting with: Mounjaro does not produce the same result at every dose. The 2.5 mg starting pen is designed to settle your system into tirzepatide, not to generate significant weight loss. The SURMOUNT-1 trial, published in the New England Journal of Medicine, found average reductions of around 20–21% body weight at 15 mg over 72 weeks, figures that come from people who reached and stayed at the highest dose, with full lifestyle support alongside. If you are on 5 mg and wondering why results feel modest, the dose ladder still has room to climb, but that is a clinical conversation, not a self-adjusting decision. You can read about what to expect at 5 mg specifically if that is where you are in the titration.
The real myth is that the medicine operates independently of everything else you do. It does not. Tirzepatide reduces appetite and slows gastric emptying; it gives you a significant biological advantage. What you do with that advantage still matters.
Protein is the single most underrated factor. When appetite drops sharply on Mounjaro, many people eat far less overall but do not pay attention to what they are eating less of. A diet that is mostly refined carbohydrates at smaller portions loses muscle alongside fat. Muscle is metabolically active tissue; losing it slows your resting metabolic rate and makes further weight loss harder. Aiming for adequate protein at each meal (lean meat, fish, eggs, Greek yoghurt, legumes) preserves muscle while tirzepatide creates the calorie deficit. The NHS obesity treatment guidance is clear that lifestyle changes are not peripheral to medicines-based weight management; they are part of the same plan.
Strength training works for the same reason. It signals the body to retain muscle even during a deficit. Cardio is fine and has cardiovascular benefits, but resistance work (even two sessions a week) has a measurably different effect on body composition. Sleep matters too. Poor sleep raises ghrelin (a hunger hormone) and lowers leptin (a satiety signal), partially counteracting what tirzepatide is doing hormonally. Seven to nine hours is not aspirational advice on this medicine; it has a direct effect on outcomes.
Alcohol is worth naming plainly. It carries calories that do not register as food in the usual sense, it impairs the liver's role in fat metabolism, and it tends to lower the inhibition that otherwise supports food choices. Plenty of people on Mounjaro drink moderately and do well; it is worth being honest about whether it is a hidden variable in a frustrating plateau. For a broader look at how Mounjaro works and what clinical results show, our full overview covers the mechanism and the trial evidence in detail.
Mounjaro is a once-weekly injection, and the day of the week does not significantly affect outcomes provided it is consistent. What does matter is how the pen is stored. Tirzepatide must be kept refrigerated at 2–8°C; a pen that has been left out or exposed to heat longer than the patient information leaflet permits may degrade silently. Keeping your pen in a dedicated spot in the fridge door, separate from food items that get moved constantly, reduces the chance of accidental temperature exposure. For the exact storage window at room temperature, the Mounjaro SmPC on the eMC is the definitive reference, not a forum post or a rough rule of thumb.
Injection technique is another small variable people rarely consider. Rotating sites between abdomen, thigh and upper arm prevents localised tissue changes that can affect absorption. Injecting into scar tissue or a repeatedly used spot is a quiet efficiency loss. If you are increasing your dose and wondering what clinical evidence says about outcomes at the next level, our page on whether increasing your Mounjaro dose increases weight loss sets out what the data actually show.
Some people are also managing a transfer from a previous clinic or restarting after a gap. In those cases, the prescriber needs to assess your history before any titration decision. At nume, our clinical team reviews every order individually, a prescriber reads your record, not software. If your current dose feels stuck and you want to understand your options, that conversation starts with a consultation, not a dose chart.
If you have been on a dose for at least four weeks, your tolerability is good, and weight loss has genuinely stalled rather than simply slowed, that is a reasonable time to ask whether titration is appropriate. The prescriber will look at your total weight reduction since starting, not just the most recent month. Progress in the early doses counts, even if it feels slow by comparison to the trial headlines. Our page on when to increase your Mounjaro dose covers the clinical reasoning behind the titration schedule in more depth.
If you are already at 10 mg or higher and results have plateaued, the focus shifts more towards the lifestyle factors above, and in some cases, a frank conversation about whether any medical factors are affecting the response. Conditions like hypothyroidism, polycystic ovary syndrome, or certain medications can affect weight independent of what Mounjaro is doing. Your prescriber is the right person to work through that with you, not a web search. If you are considering starting Mounjaro or moving your prescription, you can learn about our online prescription service and what the process involves. The free consultation is the natural first step, a prescriber reviews your situation the same day and can advise on what is realistic at your current dose and what comes next.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.